Precise quantitation of the latent HIV-1 reservoir: Implications for eradication strategies

Journal of Infectious Diseases

Volumn 212, Issue 9, 2015, Pages 1361-1365

  Crooks, Amanda M ^a   Bateson, Rosalie ^a   Cope, Anna B ^b   Dahl, Noelle P ^a   Griggs, Morgan K ^a   Kuruc, JoAnn D ^a   Gay, Cynthia L ^a   Eron, Joseph J ^a   Margolis, David M ^a,b   Bosch, Ronald J ^c   Archin, Nancie M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

HIV; IUPM; latency; QVOA; RCI; SCA

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; VIRUS RNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACUTE DISEASE; ADULT; AGED; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL ASSAY; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLOW UP; HALF LIFE TIME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LATENT VIRUS INFECTION; LEUKAPHERESIS; LIMIT OF DETECTION; LONGITUDINAL STUDY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; QUANTITATIVE VIRAL OUTGROWTH ASSAY; RESTING CELL INFECTION; SENSITIVITY ANALYSIS; SINGLE COPY ASSAY; VIRAL CLEARANCE; VIREMIA; VIRUS CARRIER; VIRUS LATENCY; DRUG EFFECTS; EVALUATION STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; ISOLATION AND PURIFICATION; MIDDLE AGED; PHYSIOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; VIROLOGY; YOUNG ADULT;

ACUTE DISEASE; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; EVALUATION STUDIES AS TOPIC; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; VIREMIA; VIRUS LATENCY; YOUNG ADULT;

EID: 84946096080     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv218     Document Type: Article

References (28)

1. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 1998; 95: 8869-73
2. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, Siliciano RF. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1995; 1: 1284-90
3. Archin NM, Vaidya NK, Kuruc JD, et al. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci USA 2012; 109: 9523-8
4. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002; 53: 557-93
5. Rong L, Perelson AS. Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput Biol 2009; 5: 16
6. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5: 512-7
7. Chun TW, Justement JS, Moir S, et al. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis 2007; 195: 1762-4
8. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999; 340: 1605-13
9. Ramratnam B, Mittler JE, Zhang L, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 2000; 6: 82-5
10. Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9: 727-8
11. Palmer S, Wiegand AP, Maldarelli F, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J ClinMicrobiol 2003; 41: 4531-6
12. Eriksson S, Graf EH, Dahl V, et al. Comparative analysis ofmeasures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 2013; 9: e1003174
13. Ho YC, Shan L, Hosmane NN, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013; 155: 540-51
14. Sanchez G, Xu X, Chermann JC, Hirsch I. Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals. J Virol 1997; 71: 2233-40
15. Kieffer TL, Kwon P, Nettles RE, Han Y, Ray SC, Siliciano RF. G?A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol 2005; 79: 1975-80
16. Archin NM, Keedy KS, Espeseth A, Dang H, Hazuda DJ, Margolis DM. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS 2009; 23: 1799-806
17. Myers LE, McQuay LJ, Hollinger FB. Dilution assay statistics. J Clin Microbiol 1994; 32: 732-9
18. Macken C. Design and analysis of serial limiting dilution assays with small sample sizes. J Immunol Methods 1999; 222: 13-29
19. Maldarelli F, Palmer S, King MS, et al.ARTsuppressesplasmaHIV-1RNAto a stable set point predicted by pretherapy viremia. PLoS Pathog 2007; 3: e46
20. Dinoso JB, Kim SY, Wiegand AM, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci USA 2009; 106: 9403-8
21. Agosto LM, Yu JJ, Dai J, Kaletsky R, Monie D, O Doherty U. HIV-1 integrates into resting CD4+ T cells even at low inoculums as demonstrated with an improved assay for HIV-1 integration. Virology 2007; 368: 60-72
22. Barton KM, Burch BD, Soriano-Sarabia N, Margolis DM. Prospects for treatment of latent HIV. Clin Pharmacol Ther 2013; 93: 46-56
23. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15: 893-900
24. Maldarelli F, Wu X, Su L, et al. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 2014; 345: 179-83
25. Wagner TA, McLaughlin S, Garg K, et al. HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 2014; 345: 570-3
26. Soriano-Sarabia N, Bateson RE, Dahl NP, et al. The quantitation of replication-competent HIV-1 in populations of resting CD4+ T cells. J Virol 2014; 24: 01900-14
27. Archin NM, Sung JM, Garrido C, Soriano-Sarabia N, Margolis DM. Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat Rev Microbiol 2014; 12: 750-64
28. Hill AL, Rosenbloom DI, Fu F, Nowak MA, Siliciano RF. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc Natl Acad Sci USA 2014; 111: 13475-80